Plagued by delays, AstraZeneca HQ costs soar to £750M as it edges toward 2020 completion

In the latest update on AstraZeneca’s delay-prone HQ project, the pharma giant revealed that the cost of construction has swelled to £750 million ($956 million) — more than double the original estimate in 2013.